- Home
- PCQ vs SGHT Comparison
PCQ vs SGHT Comparison
Compare PCQ & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCQ
- SGHT
- Stock Information
- Founded
- PCQ 2001
- SGHT 2011
- Country
- PCQ United States
- SGHT United States
- Employees
- PCQ N/A
- SGHT N/A
- Industry
- PCQ Investment Managers
- SGHT Medical Specialities
- Sector
- PCQ Finance
- SGHT Health Care
- Exchange
- PCQ Nasdaq
- SGHT Nasdaq
- Market Cap
- PCQ 163.2M
- SGHT 193.2M
- IPO Year
- PCQ N/A
- SGHT 2021
- Fundamental
- Price
- PCQ $8.67
- SGHT $3.45
- Analyst Decision
- PCQ
- SGHT Buy
- Analyst Count
- PCQ 0
- SGHT 8
- Target Price
- PCQ N/A
- SGHT $4.29
- AVG Volume (30 Days)
- PCQ 69.6K
- SGHT 109.7K
- Earning Date
- PCQ 01-01-0001
- SGHT 11-06-2025
- Dividend Yield
- PCQ 4.63%
- SGHT N/A
- EPS Growth
- PCQ N/A
- SGHT N/A
- EPS
- PCQ N/A
- SGHT N/A
- Revenue
- PCQ N/A
- SGHT $76,303,000.00
- Revenue This Year
- PCQ N/A
- SGHT N/A
- Revenue Next Year
- PCQ N/A
- SGHT $12.04
- P/E Ratio
- PCQ N/A
- SGHT N/A
- Revenue Growth
- PCQ N/A
- SGHT N/A
- 52 Week Low
- PCQ $8.19
- SGHT $2.03
- 52 Week High
- PCQ $10.50
- SGHT $7.03
- Technical
- Relative Strength Index (RSI)
- PCQ 81.59
- SGHT 36.39
- Support Level
- PCQ $8.60
- SGHT $3.38
- Resistance Level
- PCQ $8.70
- SGHT $3.65
- Average True Range (ATR)
- PCQ 0.06
- SGHT 0.16
- MACD
- PCQ 0.05
- SGHT -0.07
- Stochastic Oscillator
- PCQ 92.10
- SGHT 6.86
About PCQ PIMCO California Municipal Income Fund
PIMCO California Municipal Income Fund is a closed-end management investment company. It seeks to provide current income exempt from federal and California income tax. The fund makes investments in different sectors such as healthcare, property, education, Natural Gas, and others.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.